Brief psychotherapy administered by non-specialised health workers to address risky substance use in patients with multidrug-resistant tuberculosis: a feasibility and acceptability study by Calligaro, Gregory L et al.
RESEARCH Open Access
Brief psychotherapy administered by non-
specialised health workers to address risky
substance use in patients with multidrug-
resistant tuberculosis: a feasibility and
acceptability study
Gregory L. Calligaro1 , Zani de Wit2, Jacqui Cirota2, Catherine Orrell3, Bronwyn Myers4,5, Sebastian Decker6,
Dan J. Stein7, Katherine Sorsdahl8 and Rodney Dawson2,9*
Abstract
Background: Only 55% of multidrug-resistant tuberculosis (MDR-TB) cases worldwide complete treatment, with
problem substance use a risk for default and treatment failure. Nevertheless, there is little research on
psychotherapeutic interventions for reducing substance use amongst MDR-TB patients, in general, and on their
delivery by non-specialist health workers in particular.
Objectives: To explore the feasibility and acceptability of a non-specialist health worker-delivered 4-session brief
motivational interviewing and relapse prevention (MI-RP) intervention for problem substance use and to obtain
preliminary data on the effects of this intervention on substance use severity, depressive symptoms, psychological
distress and functional impairment at 3 months after hospital discharge.
Methods: Between December 2015 and October 2016, consenting MDR-TB patients admitted to Brewelskloof
Hospital who screened at moderate to severe risk for substance-related problems on the Alcohol, Smoking and
Substance Involvement Screening Test (ASSIST) were enrolled, and a baseline questionnaire administered. In the 4
weeks prior to planned discharge, trained counsellors delivered the MI-RP intervention. The baseline questionnaire
was re-administered 3 months post-discharge and qualitative interviews were conducted with a randomly selected
sample of participants (n = 10).
Results: Sixty patients were screened: 40 (66%) met inclusion criteria of which 39 (98%) were enrolled. Of the
enrolled patients, 26 (67%) completed the counselling sessions and the final assessment. Qualitative interviews
revealed participants’ perceptions of the value of the intervention. From baseline to follow-up, patients reported
reductions in substance use severity, symptoms of depression, distress and functional impairment.
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Conclusion: In this feasibility study, participant retention in the study was moderate. We found preliminary
evidence supporting the benefits of the intervention for reducing substance use and symptoms of psychological
distress, supported by qualitative reports of patient experiences. Randomised studies are needed to demonstrate
efficacy of this intervention before considering potential for wider implementation.
Trial registration: South African National Clinical Trials Register (DOH-27-0315-5007) on 01/04/2015 (http://www.
sanctr.gov.za)
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Introduction
It is estimated that 457,000 people developed multidrug-
resistant tuberculosis (MDR-TB) in 2017 [1]. However,
only 55% of MDR-TB cases were successfully treated to
completion in 2015, with 21% of patients either lost to
follow-up or with no outcome data. Treatment-related
factors resulting in poor adherence to MDR-TB therapy
and high default rates include excessive pill burden, in-
jectable drug delivery, prolonged treatment duration and
treatment-related side effects. In addition, behaviours
such as drug use, cigarette smoking and hazardous or
harmful patterns of alcohol use are also strongly associ-
ated with delays in diagnosis [2], more advanced disease
[3], and poor treatment outcomes in MDR-TB [4–9].
The importance of substance use as a predictor of poor
outcome in tuberculosis in general and MDR-TB in particu-
lar is recognised by the World Health Organisation. It has
emphasised the need for a multisectoral approach to im-
proving TB control, with one of its Sustainable Development
Goals (SDGs) being to strengthen the prevention and treat-
ment of substance use disorders including narcotic drug
use, tobacco smoking and the harmful use of alcohol [1].
Surprisingly, given the considerable global effort to de-
velop new drugs and regimens MDR-TB, there has been
limited research on interventions to modify behaviours
and improve treatment adherence in MDR patients with
problematic substance use. Evidence-based strategies for
addressing problem substance use amongst patients with
TB may include methadone treatment for hospitalised
opioid dependence [10], smoking cessation interventions
through programmatic care [11], and screening and brief
interventions to address hazardous and harmful alcohol
use [12]. Few intervention studies have addressed sub-
stance use within the context of TB in South Africa:
those that have been conducted are limited to alcohol
and tobacco amongst patients with drug-susceptible TB
who are being treated in outpatient settings [13]. Given
the limited literature, further work is needed, particularly
in low- and middle-income countries, where there are
limited specialised mental health clinicians.
There is growing evidence that screening and brief in-
terventions (SBI) for substance-related problems can be
delivered effectively by non-specialised health workers
[14]. These interventions are typically based on
cognitive-behavioural and motivational interviewing
techniques. A number of studies have been conducted in
South Africa investigating the effectiveness of SBI
amongst patients presenting to emergency centres [15],
women receiving antenatal care [16], people receiving
treatment for human immunodeficiency virus (HIV) and
other chronic diseases in primary care settings [17–19],
and hospitalised inpatients at a district-level hospital
[20] and TB patients [12, 13].
Such interventions have not yet been evaluated in
MDR-TB cohorts where the incidence of substance use
is high. Unpublished data from our University of Cape
Town Lung Institute drug-sensitive TB trial cohort
showed that 17% of patients who actively deny drug use
during informed consent have positive urine drug
screens for substances such as cannabinoids, cocaine
and amphetamines. A previous study from our setting
showed that alcohol and other drug use were independ-
ently associated with MDR-TB treatment default [4].
The median time to default in this study was 257 days
(or relatively early in the treatment phase of 2 years) and
25% of patients defaulted during initial hospitalisation
either by refusing treatment or by absconding.
Psychosocial support in general, and addressing sub-
stance use and depression in particular, form an import-
ant but neglected area of patient-centred care in drug-
resistant TB [21]. The psychosocial issues challenging
MDR-TB patients are multifactorial and include difficul-
ties caused by the illness itself, concomitant alcohol and
substance use, the neuropsychiatric side effects of antitu-
berculous drugs (like isoniazid, cycloserine or terizi-
done), as well as the stigma attached to the disease.
To address this gap, and as first steps towards inter-
vening with this high risk population, we conducted an
uncontrolled, single-arm feasibility test of a motivational
interviewing and relapse prevention therapy (MI-RP)
intervention for problem substance use. This paper re-
ports on the (i) the feasibility of recruiting and retaining
MDR-TB patients for a substance use intervention; (ii)
preliminary information on the intervention’s substance
use, mental health and TB outcomes; and (iii) participants’
perceptions of the acceptability of the intervention.
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Methods
Trial design
An uncontrolled, single-arm feasibility test of a motiv-
ational interviewing and relapse prevention therapy (MI-
RP) intervention for problem substance use.
Setting
The study was conducted at Brewelskloof Hospital, a
specialised TB hospital located in the town of Worcester in
the Overberg District of the Western Cape Province, South
Africa, which provides inpatient care for patients with
drug-resistant TB. The hospital has 48 MDR-TB beds and
admits ~ 150 patients per year with MDR-TB [4].
Patients
Consecutive patients with MDR-TB (diagnosed on Xpert
MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) and/or
liquid culture (BACTEC MGIT 960 system) [22]) admit-
ted for the intensive phase of their treatment were re-
cruited. Patients were eligible if they were ≥ 18 years of
age and if they were at moderate to high risk for sub-
stance abuse, as measured by the Alcohol, Smoking and
Substance Involvement Screening Test (ASSIST) [23].
The ASSIST consists of eight questions covering to-
bacco, alcohol, cannabis, cocaine, amphetamine-type
stimulants, inhalants, sedatives, hallucinogens, opioids
and ‘other drugs’. A risk score is provided for each sub-
stance, and scores are grouped into ‘low risk’, ‘moderate
risk’ or ‘high risk’. The ASSIST takes approximately 5 to
10 min to administer. The ASSIST has been previously
been validated for use in South Africa [24]. Patients with
known psychiatric illness and/or significant medical co-
morbidities affecting insight, mobility or access to con-
tinued care were excluded from the study.
Procedures
After hospital admission, lay counsellors approached pa-
tients for study eligibility screening. After obtaining the
patient’s consent, the counsellor administered the ASSI
ST. Low-risk substance users were thanked for their
time and encouraged to maintain low risk usage, whilst
patients scoring in the moderate and high risk range
were invited to participate in the intervention. Patients
who provided written consent were enrolled in the study
and were asked to provide locator information. Field
staff then administered a baseline questionnaire. Four
weeks prior to their anticipated discharge date, patients
received a motivational interviewing and relapse preven-
tion (MI-RP) intervention in their preferred language
(English, Afrikaans or Xhosa). Participants were contacted
for a 3-month post-discharge follow-up assessment
(3MFU) in which the baseline assessment was re-
administered by a fieldworker not involved in the counsel-
ling (Fig. 1). MDR-TB treatment retention was recorded,
and treatment outcomes (culture conversion, completion
and cure) were obtained from the clinic register. Urine
sample collection for illicit substances was performed at
baseline, hospital discharge and at the 3MFU. The qualita-
tive assessment involved in-depth interviews (guided by a
semi-structured questionnaire) by ZdW in a random sam-
ple of 10 participants at the 3MFU end-point. Interviews
were audiotaped and transcribed verbatim before the text-
ual data was analysed qualitatively. Study procedures were
overseen by the Human Research Ethics Committee of
the University of Cape Town (UCT-HREC 004/2015).
The clinical trial was registered with the South African
National Clinical Trials Register (SANCTR) (DOH-27-
0315-5007).
Intervention
The MI-RP intervention consisted of 4 weekly sessions,
each lasting between 45 and 60 min. Both MI and RP
are considered evidence-based interventions for sub-
stance use disorders, and there is emerging evidence that
the combination of these two approaches is effective for
both substance use disorders [25] and helpful for medi-
cation adherence [26]. More specifically, motivational el-
ements were included to build readiness for changing
substance use and the RP content was included to help
participants identify high-risk situations for substance
use and external and internal triggers that may lead to
thoughts and urges to use substances, and to teach them
cognitive-behavioural strategies for managing these trig-
gers and situations. During the intervention sessions, the
counsellor provided feedback on the participants’ risk
for substance-related harms, helped the participant set
goals and identify barriers to change, and guided the
participant in identifying high risk situations and triggers
for substance use while teaching the participant tech-
niques for managing both external and internal factors
that place them at risk for relapse. Participants were pro-
vided with opportunities within the counselling sessions
to practice these techniques. These techniques were also
summarised in a written information booklet which in-
cluded additional take-home activities to cement these
new skills.
Counsellor training and fidelity
Two counsellors were each trained to deliver the inter-
vention in the patient’s preferred language; one spoke
English or Afrikaans, whilst the other spoke isiXhosa.
Both counsellors had at least a Bachelor qualification in
either psychology or social work, and originated from
the communities in the area. They received 40 h of
training from BM and KS, followed by a proficiency test.
Training included (i) substance use and the risks associ-
ated with substance use; (ii) using and scoring the ASSI
ST; (iii) ethics of research and importance of
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maintaining confidentiality and reporting adverse events;
(iv) the intervention protocol; and (v) the process of
managing distressed participants and referring patients
for specialised care. To ensure intervention fidelity,
counsellors completed a checklist to ensure all aspects
of the intervention were provided. Additionally, all ses-
sions were tape-recorded and random samples were se-
lected for fidelity checking.
Measures
To assess intervention feasibility, we recorded eligibility,
recruitment, and treatment retention rates as well as
study retention rates at follow-up. Substance use severity
at baseline and 3MFU was measured using the ASSIST
[23]. The following secondary outcomes were also mea-
sured at both time-points: Centre for Epidemiological
Studies Depression Scale (CES-D), a measure of the
most common symptoms of depression [27]; Fagerström
Test for Nicotine Dependence (FTNF), a measure of the
intensity of physical addition to nicotine [28]; EQ-5D 3L,
a standardised instrument combining both descriptive
and visual components as a measure of quality of life
[29]; Sheehan Disability Scale (SDS), a measure of func-
tional impairment in three inter-related domains: work,
social and family life [30]; Self-Reporting Questionnaire
20 (SRQ20), a measure of psychological distress [31]. In
addition, the Stages of Change Readiness and Treatment
Eagerness Scale (SOCRATES), an experimental instrument
designed to assess readiness for change [32], and the
Multidimensional Scale of Perceived Social Support,
(MSPSS) a measure of perceived social support using
three subscales, namely: family, friends and significant
others [33] were used. MDR-TB treatment outcome
(culture conversion) was also recorded at the 3-
month follow-up time point (which occurred at least
6 months after MDR-TB was initiated), and patients
were followed up in the clinic register to determine
final treatment outcome [34] (Supplementary file).
Data analysis
Descriptive statistics were used to assess the number of
potentially eligible patients (based on screeners), feasibil-
ity of recruitment (number and reasons for refusal to
participate), participation (number of sessions attended)
and completion rates. Frequency distributions and de-
scriptive statistics were calculated for categorical and
continuous variables. Paired sample t tests (for paramet-
ric data) and Wilcoxon signed rank tests (for non-
parametric data) were used to assess initial effect of the
intervention on the primary and secondary outcome var-
iables. For patients reporting use of more than one sub-
stance, the substance for which they obtained the
highest ASSIST score was compared. Statistical analyses
were performed using GraphPad Prism (V·5·0, GraphPad
Software, USA) and Stata (V.12.1, Stata Corp., College
Station, TX, USA) [35]. Qualitative data analysis was
Fig. 1 Diagram of study outline
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conducted using the framework approach (familiarisa-
tion, identifying a thematic framework, indexing, chart-
ing, mapping and interpretation of data) [36], aided by
NVivo 11.0 (a software programme). Initially, interview
responses were read for emergent themes, which were
then coded. To establish inter-coder reliability, each
transcript was coded by two individuals who met to
compare notes, establish a degree of agreement and re-
solve coding differences.
Role of the funding source
The funders of the study had no role in study design,
data collection, data analysis, data interpretation, or writ-
ing of the report. The corresponding author had full ac-
cess to all the data in the study and had final
responsibility for the decision to submit for publication.
Results
Patient flow and feasibility
During the study period, 60 consecutive inpatients were
screened, of which 40 (70%) met substance use criteria
for participation and were recruited to the intervention
study (Fig. 2). 39/40 (97%) of the eligible patients
received at least one counselling session; 32/40 (80%)
completed all four counselling sessions and 26/40 (65%)
completed the 3-month follow-up (overall study reten-
tion rate). In total, 14/40 recruited patients (33%) were
excluded from the final analysis: 5 (13%) because they
were discharged before the inpatient counselling inter-
vention was completed, 3 (8%) because they were ultim-
ately found not to have MDR-TB (one false-positive
genotypic for rifampicin resistance, and two cases of ex-
tended drug resistance), 3 (8%) because they were lost to
follow-up and 3 (8%) because they withdrew consent.
One patient withdrew consent after the ASSIST score
was administered but before any counselling sessions
were administered, and two withdrew consent during
the inpatient intervention.
Sample description
The last column in Table 1 shows the demographic
characteristics of the group of patients that completed the
MI-RP intervention. There were no differences between
the demographics of the overall sample and the groups of
patients that were excluded or who completed the inter-
vention (Table 1). The majority of patients were male (n =
Fig. 2 CONSORT diagram
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14; 54%), with a mean (SD) age of 36.3 (10.6), and of mixed
race or “coloured” (n = 20; 77%). [The term “coloured” re-
fers to an ethnic group of people who possess some degree
of sub-Saharan ancestry, but not enough to have been con-
sidered Black African during apartheid. It is a commonly
used marker of race identity in South Africa]. Almost all
patients had some school education (n = 25; 95%), with
mean (SD) school grades completed of 7.8 (3); the majority
were unemployed (n = 16; 62%) and lived in formal hous-
ing (n = 20, 77%). The mean (SD) ASSIST score was 19
(6.1), indicating moderate risk; only 2 (8%) patients were
high risk (ASSIST score ≥ 27). Alcohol was the most com-
monly used substance, with 25 patients (96%) reporting al-
cohol use in the 3 months before enrolment; 5 patients
(42%) reporting cannabis use, 1 (4%) reporting cocaine use,
3 (12%) reporting amphetamine use and 2 (8%) reporting
inhalant use. Regular (either daily or several times per
week) alcohol, cannabis and amphetamine use was re-
ported in 16 (62%), 4 (16%) and 1 (4%) of patients, respect-
ively. Four (15%) patients regularly used more than one
substance.
Preliminary effects
The ASSIST score decreased following the intervention
(pre-intervention median (IQR) 17.5 (15–24) versus 6
(6–8)). Depressive symptomatology improved, with the
median (IQR) CES-D score significantly lower post-
intervention [23.5 (18–34) vs. 17 (13–22)]. Several other
secondary measures also improved post-intervention
(Table 2). There were also significant improvements in
nicotine dependence, health status, functional impairment,
psychological distress, readiness for change and perceived
social support (Table 2). Only two patients (8%) had posi-
tive urine screening for a drug of abuse at follow-up. All
patients that completed follow-up were adherent to treat-
ment, culture-converted and were ultimately cured.
Patients’ experience and acceptability
Three themes emerged from qualitative data that reflect
patients’ perceptions of the acceptability of the counsel-
ling programme. The first theme highlights patients’
levels of motivation for addressing their substance use.
The second theme describes the acceptability of the pro-
posed counselling programme. The third theme de-
scribes recommendations for modifying the counselling
programme.
Motivation for behaviour change
High levels of motivation for addressing substance use
were reported by all patients. Reasons put forward to






Median (IQR) 28 (26–39) 36 (27–43)
Gender
Males, n (%) 6 (43%) 14 (54%)
Education
Any schooling, n % 13 (93%) 25 (97%)
Highest grade completed, median (IQR) 8 (6–9) 7 (6–11)
Housing
Formal housing, n % 8 (57%) 20 (77%)
No. of people sharing house, med (IQR) 4 (3–6) 4 (3–7)
No. of rooms in house, med (IQR) 3 (1–5) 3 (2–4)
Employment
Employed, n % 3 (21%) 10 (38%)
Unemployed, 11 (79%) 15 (58%)
Full-time student, n % 1 (3%) 1 (4%)
Smoking status
Current smoking, n % 5 (36%) 13 (50%)
Previous smoking, n % 4 (29%) 7 (27%)
Never smoked, n % 5 (36%) 6 (23%)
aFourteen patients excluded after enrolment: 5 (13%) because they were discharged before the inpatient counselling intervention was completed, 3 (8%) because
they were ultimately found not to have MDR-TB (one false-positive genotypic for rifampicin resistance, and two cases of extended drug resistance), 3 (8%)
because they were lost to follow-up and 3 (8%) because they withdrew consent
There were no statistically significant differences
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why they agreed to receive counselling included “to want
to resist it, to bury alcohol away forever” and “I wanted
to quit alcohol, but I didn’t know how to do that”. This
motivation for changing alcohol use seemed to go hand
in hand with their health-related concerns and the desire
to live a healthier life. This is illustrated by two patients
who had the following to say about why they agreed to
access counselling:
“I decided to participate in the study because I rea-
lised it was the right way to live your life, to let go
of things that are wrong; like drugs, alcohol, and
using syringes [Patient 58]”.
“I decided to take part because I didn't want to be
like I was anymore. And the programme really
helped me to stop doing the things I was doing be-
fore. [Patient 45]”.
Acceptability of counselling programme
Patients reported positive experiences with the counsel-
ling programme, noting that “it was just so nice” and “I
was happy all those times when I went for my sessions”.
A few expressed that their stay in the hospital provided
the space and time to reflect on their life and their
health. The counselling sessions facilitated this reflection
and ultimately their change in behaviour. As some
patients reflected:
“I learned a lot from the sessions. I was always
someone who liked to make trouble, do things like
drinking and smoking, but now I choose to do
things like taking a walk, gardening or playing foot-
ball” [Patient 58].
“They helped me a lot. Number one, I no longer do
alcohol. Even if a person is drinking, I don’t have
that thing to say let me also take a sip [Patient 47]”.
There was consensus that the content, structure and
delivery of the programme were acceptable. Patients
could not identify any aspect that was redundant or not
applicable to their needs. The counsellor delivering the
programme content was acknowledged for her kindness,
understanding, and ability to listen and explain the
programme content clearly. These characteristics were
conveyed by the following patients:
“I was a bit nervous at the beginning, but she made
me feel very comfortable, she explained things to
me so well. [Patient 34]”.
“I felt good because I could talk to her and she
always understood what I was talking about.
[Patient 33]”.
The written information booklet that accompanied the
counselling sessions was considered highly valuable to
patients, not only while they were receiving the counsel-
ling sessions in the hospital but following discharge as
Table 2 Changes in primary and secondary outcomes in 26





ASSISTb (alcohol and substance use)
Highest scorea 17.5 (15–24) 6 (6–8)
Alcohol 17.5 (15–23) 6 (6–8)
Cannabis 0 (0–6) 0 (0–6)
Amphetamines 0 (0–0) 0 (0–0)
CES-D (depression) 23.5 (18–34) 17 (13–22)
FTNDc (nicotine dependence) 2 (2–4) 1 (1–2)
EQ-5D 3L (health status
Descriptive elements 5.5 (5–7) 5 (5–5)
Visual analogue scale 70 (57–80) 90 (80–100)
SHS (disability)
Work/school 0 (0–3) 0 (0–0)
Social life 2.5 (0–5) 0 (0–3)
Family life/home responsibilities 4 (0–7) 0 (0–3)
SRQ-20 (psychological distress) 8 (4–10) 3 (1–4)
SOCRATES (readiness for change)
Recognition 20 (19–22) 15 (15–19)
Ambivalence 13 (11–15) 8 (4–10)
Taking steps 35 (32–39) 40 (38–40)
MDSPSS (social support)
Significant other 8 (4–10) 3 (1–4)
Family 7 (6–7) 7 (6–7)
Friends 6 (4–6) 5 (4–6)
Total 6 (5–6) 6 (6–7)
Abbreviations: ASSIST Alcohol, Smoking and Substance Involvement Screening
Test, a measure of problematic alcohol and drug use [23], CESD-D Centre for
Epidemiological Studies Depression Scale, a measure of the most common
symptoms of depression [27], FTND Fagerström Test for Nicotine Dependence,
a measure of the intensity of physical addition to nicotine [28], EQ-5D 3L, a
standardised instrument combining both descriptive (lower score indicates
better health) and visual components as a measure of health outcome [29],
SDS Sheehan Disability Scale, a measure of functional impairment in three
inter-related domains: work, social and family life [30], SRQ-20 Self-Reporting
Questionnaire 20 (SRQ20), a World Health Organisation screening test for
anxiety and depression disorders [31], SOCRATES Stages of Change Readiness
and Treatment Eagerness Scale, an experimental instrument designed to
assess readiness for change [32], and MSPSS Multidimensional Scale of
Perceived Social Support, a brief self-report questionnaire with 12 items that
subjectively measure perceived social support using three subscales, namely,
family, friends and significant others (MSPSS) [33]
aFour (15%) patient regularly used more than one substance before the
intervention; the substance with the highest ASSIST score was used
bNo patient reported sedative, hallucinogen, opiate or methaqualone use
cOf the 11 smoking patients who scored > 1 on the Fagerström test
at baseline
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well. A few described using the booklet as a resource to
refer to when they are facing challenges in their life. Sev-
eral patients described how they were still referring to
the booklet:
“I liked the part about experience, and what you are
going to do when you leave the hospital, and writing
every day about my experiences, what I did that day.
[Patient 58]
The things in the booklet still have value for me, I
recently took out the booklet again, and just yester-
day I was thinking about the booklet again, and I
went through it and looked at the old work assign-
ments I did. [Patient 37]”.
Recommendations for modifying the counselling
programme.
Although many patients thought that the duration of the
intervention was appropriate, approximately half
expressed that additional sessions would have been valu-
able. Unfortunately, whether these sessions should be
conducted in hospital or after they were discharged into
the community was not explored in the present study.
The preference for additional sessions is expressed by
the following patient:
“I think there should be more sessions. I enjoyed
the counselling very much, I liked it and looked for-
ward to it [Patient 37]”.
One of the challenges that some of the patients
expressed during the counselling sessions was complet-
ing the homework tasks due to low levels of literacy.
Four patients reported that they identified someone in
the hospital, either another patient or a healthcare
worker to assist them to complete the tasks.
Discussion
This study is the first to examine an MI-RP intervention
for problem substance use for hospitalised patients with
MDR-TB had two main findings. First, our study dem-
onstrates feasibility and acceptability of this intervention.
Moderate retention rates indicate that it is possible to
recruit, retain and follow-up patients with MDR-TB. Al-
most all eligible patients were willing to participate in a
counselling intervention to reduce their substance use,
demonstrating the acceptability of the intervention. This
was reinforced by qualitative report, which emphasised
that patients found the content, structure and delivery of
the intervention acceptable. Over three-quarters of pa-
tients who consented to participate in MI-RP completed
all four sessions, and the majority of patients expressed a
desire for additional intervention sessions, which further
supports the acceptability and perceived utility of this
intervention. Second, findings from this small pilot study
suggested that a MI-RP intervention shows preliminary
outcomes that are promising. Following the intervention,
there was a significant reduction in composite risk
scores for substance use, with patients on average mov-
ing from moderate risk use to low risk use. There was
also a significant reduction in depressive symptomatol-
ogy and improvements in measures of psychological dis-
tress, functional impairment, nicotine dependence,
readiness for change and perceived social support.
Acceptability and feasibility of this intervention is con-
sistent with a range of other work on task-sharing in
low- and middle-income countries [37, 38]. The use of
counsellors was highly acceptable to patients, supporting
the use of non-speciality health workers to deliver such
an intervention. The feasibility of employing non-
speciality workers rather than mental health profes-
sionals for this intervention has important positive im-
plications for scalability in resource-limited
environments such as South Africa.
Preliminary evidence of efficacy of a counselling inter-
vention in improving substance use severity is also con-
sistent with previous work, albeit in patients without TB
[16, 20]. There are no studies of counselling interven-
tions in MDR-TB that have focused specifically on sub-
stance use, and the few studies that have evaluated
counselling interventions in drug-resistant TB have fo-
cused only adherence and treatment outcomes in outpa-
tients [39–41]. Hospitalised patients are a particularly
attractive target population for a substance abuse inter-
vention because there is restricted availability and op-
portunity for substance use, and a planned intervention
has the potential to prepare patients for discharge by
preventing relapse and lifestyle management.
The finding that alcohol was the most commonly used
substance is significant as it is one of the risk factors for
MDR-TB [42]. Drug resistance may result from inter-
ruptions in drug-sensitive treatment resulting from alco-
hol use [43], and treatment default is also attributed to
alcohol use [44]. There is an urgent need for effective
intervention strategies to address alcohol abuse amongst
the MDR-TB patients to bring about better treatment
compliance.
Several limitations of this study deserve emphasis.
First, the sample size was small, and there was no com-
parison group; further adequately powered randomised
controlled trials are needed to confirm these findings.
Second, data on patients not enrolled in or not complet-
ing the study intervention were not collected; improve-
ments in substance use outcomes could represent
regression to the mean or a non-specific effect. Improve-
ments in depression and other measures could be re-
flective of response to antituberculous treatment and
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general improvement in health and are also confounded
by the differences in setting between baseline and
follow-up (inpatient vs. outpatient status). Previous stud-
ies have shown that psychological symptoms in MDR-
TB are more severe at diagnosis and during the early
stages of the disease [21]. Third, only illicit substances
were able to be tested on urine; without a measure to
confirm reductions in alcohol use, the treatment effect
could not be objectively confirmed. Fourth, there was
also a better than expected MDR-TB treatment outcome
in the study group, with no treatment failures, perhaps
indicating a sub-set of more impressionable, willing and
adherent patients. Lastly, our preliminary findings may
not be generalisable to all patients with MDR-TB; there
has been a global move away from hospitalising patients
with MDR-TB, and South Africa has decentralised and
deinstitutionalised treatment since 2011 [45]; the study
population therefore represents a relatively small pro-
portion of the patients under care in the National Treat-
ment Programme with MDR-TB.
Conclusions
To the best of our knowledge, this study is the first to
demonstrate that a counselling intervention delivered by
non-specialist health workers to address substance use
in MDR-TB is feasible and acceptable, and potentially
promising for reducing substance use and improving
mental health. However, as this was an uncontrolled,
single-arm study, findings remain preliminary, and the
efficacy of MI-RP for reducing problematic substance
use will need to be studied. The evidence gained from
this feasibility test will form the basis for future studies
of task-sharing MI-RP-based interventions such as group
MI-RP, outpatient MI-RP and nurse-driven MI-RP,
which could be accessible to all MDR-TB patients.
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